# US 2014/0234213 A1 · Rationally-Designed Anti-Mullerian Inhibiting Substance Type II Receptor Antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0234213 A1
- Document ID: US20140234213A1
- Status: Published application
- Kind: A1
- Application number: 14/122,286
- Filed: 2012-05-29
- Published: 2014-08-21
- Earliest claimed: 2011-05-27
- Assignees: Fox Chase Cancer Center
- Applicants: Fox Chase Cancer Center
- Inventors: Gregory P. Adams; Heidi H. Simmons; Matthew K. Robinson; Roland Dunbrack; Andreas Lehmann
- Web page: https://patentgrep.com/patent/US20140234213A1

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2318/10: Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods for generating hybrid antibodies are provided.

## Claims

### Claim 1

An isolated antibody which is immunologically specific for Mullerian Inhibiting Substance Type II Receptor (MISIIR), wherein said antibody comprises at least one region from Mullerian Inhibiting Substance (MIS) in place of at least one complementarity determining region (CDR).

### Claim 2 (depends on 1)

The antibody of claim 1, selected from the group consisting of a monoclonal antibody, a single chain Fv antibody, a diabody, a tribody, a tetrabody, a single domain antibody, a minibody, an scFv-Fc molecule, a Fab fragment, a Fab′ fragment and a F(ab′)2 fragment.

### Claim 3 (depends on 2)

The antibody of claim 2, which is a single chain Fv antibody.

### Claim 4 (depends on 1)

The antibody of claim 1, wherein said antibody is immunologically specific for the extracellular domain of MISIIR.

### Claim 5 (depends on 1)

The antibody of claim 1, wherein said region from MIS comprises amino acids 533-550 of SEQ ID NO: 5.

### Claim 6 (depends on 1)

The antibody of claim 1, wherein said antibody has at least 90% identity with SEQ ID NO: 7, 8, or 9.

### Claim 7 (depends on 1)

The antibody of claim 1, wherein said antibody is conjugated to at least one radioisotope, purification tag, imaging agent, contrast agent, chemotherapeutic agent, or cytotoxic molecule.

### Claim 8 (depends on 1)

The antibody of claim 1, wherein said antibody has at least 90% identity with SEQ ID NO: 7.

### Claim 9 (depends on 8)

The antibody of claim 8, wherein said antibody comprises at least one mutation selected from the group consisting of K109R, R118N, A121L, L111M, S113Y, S120V, and V124Y.

### Claim 10 (depends on 1)

A composition comprising at least one antibody of claim 1 and at least one pharmaceutically acceptable carrier.

### Claim 11 (depends on 10)

A method for inhibiting a cancer in a subject comprising administering to a subject in need thereof a therapeutically effective amount of the composition of claim 10.

### Claim 12 (depends on 11)

The method of claim 11, wherein said cancer is selected from the group consisting of breast, prostate, and gynecological cancers.

### Claim 13 (depends on 11)

The method of claim 11, further comprising administration of at least one chemotherapeutic agent.

### Claim 14 (depends on 1)

An isolated nucleic acid molecule encoding the antibody of claim 1.

### Claim 15 (depends on 14)

A vector comprising the nucleic acid molecule of claim 14.

### Claim 16 (depends on 1)

A method for imaging cancer in a patient comprising administering to a patient an antibody of claim 1, said antibody optionally comprising a detectable label.

### Claim 17 (depends on 16)

The method of claim 16, wherein said detectable label comprises a radioisotope.

### Claim 18 (depends on 1)

A method for detecting the presence or absence of MISIIR in a biological sample comprising incubating said biological sample with the antibody of claim 1, wherein said antibody optionally comprises a detectable label.

### Claim 19

A method for generating a hybrid antibody immunologically specific for a target protein, said method comprising replacing at least one complementarity determining region (CDR) of a first antibody with at least one amino acid sequence from a ligand of said target protein.

### Claim 20 (depends on 10)

A method for promoting the survival or growth of neurons in a subject comprising administering to a subject in need thereof a therapeutically effective amount of the composition of claim 10.

### Claim 21 (depends on 10)

A method of inhibiting a motor neuron disease comprising administering to a subject in need thereof a therapeutically effective amount of the composition of claim 10.
